[go: up one dir, main page]

ECSP12011840A - Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos - Google Patents

Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos

Info

Publication number
ECSP12011840A
ECSP12011840A ECSP12011840A ECSP12011840A EC SP12011840 A ECSP12011840 A EC SP12011840A EC SP12011840 A ECSP12011840 A EC SP12011840A EC SP12011840 A ECSP12011840 A EC SP12011840A
Authority
EC
Ecuador
Prior art keywords
arilindenopirimidinas
heteroarilo
antagonists
receiver
replaced
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Jackson
Brian Christopher Shook
Aihua Wang
Mark Powell
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP12011840A publication Critical patent/ECSP12011840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se relaciona con una nueva arilindenopirimidina, A, y sus usos terapéuticos y profilácticos. Los trastornos que se tratan y/o previenen incluyen la enfermedad de Parkinson.en donde X, R2, R3, y R4 son como se definieron en la descripción.
ECSP12011840 2009-10-29 2012-04-27 Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos ECSP12011840A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25593509P 2009-10-29 2009-10-29

Publications (1)

Publication Number Publication Date
ECSP12011840A true ECSP12011840A (es) 2012-06-29

Family

ID=43128297

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011840 ECSP12011840A (es) 2009-10-29 2012-04-27 Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos

Country Status (9)

Country Link
US (1) US20110105494A1 (es)
CN (1) CN102596934A (es)
AU (1) AU2010313578A1 (es)
CA (1) CA2779124A1 (es)
EC (1) ECSP12011840A (es)
IL (1) IL219342A0 (es)
MX (1) MX2012005004A (es)
PH (1) PH12012500842A1 (es)
WO (1) WO2011053511A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102153040B1 (ko) 2013-11-28 2020-09-07 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN111183130B (zh) * 2017-09-07 2023-10-20 恒翼生物医药(上海)股份有限公司 苯并杂环衍生物及包含其的医药组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) * 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
WO2011053511A1 (en) 2011-05-05
CA2779124A1 (en) 2011-05-05
AU2010313578A1 (en) 2012-05-24
US20110105494A1 (en) 2011-05-05
PH12012500842A1 (en) 2017-08-23
CN102596934A (zh) 2012-07-18
MX2012005004A (es) 2012-06-12
IL219342A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
PA8548901A1 (es) Ligandos del receptor 5-ht y sus usos
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
AR072699A1 (es) Antagonistas especificos del receptor 4 del factor de crecimiento de los fi-broblastos (fgf-r4)
ECSP14025178A (es) Antagonistas del receptor st2l y métodos de uso
CO6321169A2 (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas de receptores de adenosina a2a
ECSP11011243A (es) Agonistas y antagonistas de los receptores s1p5 y metodos de usos similares aplicaciones relacionadas
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
UY31421A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
CL2008001007A1 (es) Compuestos derivados de furo[2,3-b] piridina, moduladores del receptor canabinoide-1; y su uso para tratar psicosis, deficit de memoria, trastornos cognitivos, entre otras enfermedades.
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo
ECSP12011841A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON HETEROCICLILO Y SU USO COMO ANTAGONISTAS DE LOS RECEPTORES DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011843A (es) Arilindenopirimidinas sustituidas con arilo y su uso como antagonistas de receptores de adenosina a2a altamente selectivos
CR20110258A (es) METILENAMINAS DE TIENO[2,3-d] PIRIMIDINA Y SU USO COMO ANTAGONISTA DE RECEPTORES DE ADENOSINA A2a